Liver-9-Line 2nd Generation
The Liver-9-Line 2nd Generation immunoblot test is a membrane-based enzyme immunoassay for the semi-quantitative determination of IgG autoantibodies against nine test antigens in human serum or plasma. It is used in cases of suspected autoimmune liver disease such as type 1 or type 2 autoimmune hepatitis (AIH-1, AIH-2), primary biliary cirrhosis (PBC), and primary sclerosing cholangitis (PSC).
In particular, the simultaneous detection of autoantibodies against specific marker antigens makes it possible to differentiate between type 1 and type 2 AIH and to rule out other liver diseases.
Elevated titers of antinuclear antibodies (ANA) and/or anti-smooth muscle antibodies (ASMA) are typical of AIH-1. With the Liver-9-Line 2nd Generation test, detection of antibodies against the individual smooth-muscle antigens F-Actin, alpha-actinin, and tropomyosin serves to differentiate this disease. The analysis of these diagnostically relevant biomarkers also allows for assessment of disease activity and evaluation of further progression. Autoantibodies against soluble liver antigen (SLA), also known as liver-pancreas antigen (LP) are also highly specific markers for AIH-1.
Antibodies against liver-kidney microsome type 1 (LKM-1) and liver cytosolic protein type 1 (LC1) are characteristic of AIH-2. They are indicative of severe progression and LC1 antibody titers correlate with disease activity.
Anti-mitochondrial antibodies of the M2 subtype (AMA-M2) indicate PBC. They are absent in up to 5 % of PBC patients. In such cases, the highly specific antibodies against nuclear body antigen Sp100 and nuclear pore antigen gp210 are diagnostically important.
Specifications
Product Number |
ORG 722 |
Tests | 8 strips / ORG 722-08, 16 strips / ORG 722-16 |
Calibration | internal |
Calculation | semi-quantitative |
Coating |
alpha-actinin, F-actin, nuclear pore antigen gp210, LC1 (liver cytosolic protein type 1), LKM-1 (recombinant) , M2 proteins (PDC-E2, BCOADC-E2, OGDC-E2), SLA/LP, nuclear body antigen Sp100, tropomyosin |
|
|
Instruction for Use Revision 4. Earlier versions and additional languages can be found in the document archive.
|